 Matthew Rossman
Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 23 | 2023 | 1657 | 3.000 |
Why?
| | Aging | 15 | 2023 | 1670 | 2.360 |
Why?
| | Antioxidants | 6 | 2023 | 564 | 2.310 |
Why?
| | Leg | 15 | 2022 | 234 | 2.250 |
Why?
| | Endothelium, Vascular | 15 | 2023 | 907 | 2.170 |
Why?
| | Vasodilation | 18 | 2022 | 457 | 2.150 |
Why?
| | Nitric Oxide | 14 | 2023 | 892 | 1.780 |
Why?
| | Mitochondria | 5 | 2023 | 786 | 1.720 |
Why?
| | Oxidative Stress | 12 | 2023 | 1179 | 1.640 |
Why?
| | Brachial Artery | 7 | 2022 | 181 | 1.570 |
Why?
| | Vascular Stiffness | 8 | 2023 | 425 | 1.430 |
Why?
| | Muscle Fatigue | 5 | 2017 | 91 | 1.420 |
Why?
| | Vascular Diseases | 5 | 2023 | 241 | 1.390 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 71 | 1.280 |
Why?
| | Blood Vessels | 3 | 2020 | 187 | 1.280 |
Why?
| | Femoral Artery | 9 | 2016 | 175 | 1.090 |
Why?
| | Ascorbic Acid | 3 | 2021 | 120 | 1.060 |
Why?
| | Regional Blood Flow | 14 | 2022 | 418 | 1.050 |
Why?
| | Muscle, Skeletal | 14 | 2023 | 1517 | 1.030 |
Why?
| | Movement | 8 | 2022 | 248 | 1.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 1136 | 0.940 |
Why?
| | Reactive Oxygen Species | 10 | 2023 | 576 | 0.910 |
Why?
| | NAD | 1 | 2023 | 67 | 0.900 |
Why?
| | Endothelial Cells | 7 | 2023 | 732 | 0.890 |
Why?
| | Citrulline | 1 | 2022 | 41 | 0.840 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 101 | 0.840 |
Why?
| | Cellular Senescence | 3 | 2023 | 151 | 0.830 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 33 | 0.810 |
Why?
| | Sodium Nitrite | 1 | 2021 | 36 | 0.770 |
Why?
| | Bronchi | 1 | 2022 | 242 | 0.750 |
Why?
| | Aged | 30 | 2023 | 19657 | 0.720 |
Why?
| | Stroke Volume | 4 | 2019 | 513 | 0.700 |
Why?
| | Exercise Tolerance | 5 | 2023 | 233 | 0.650 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 343 | 0.630 |
Why?
| | Mitochondria, Muscle | 5 | 2021 | 97 | 0.630 |
Why?
| | Dietary Supplements | 5 | 2023 | 467 | 0.630 |
Why?
| | Heating | 1 | 2017 | 18 | 0.610 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 1801 | 0.570 |
Why?
| | Muscle Contraction | 7 | 2021 | 413 | 0.560 |
Why?
| | Fatigue | 2 | 2014 | 297 | 0.530 |
Why?
| | Asthma | 2 | 2022 | 2157 | 0.520 |
Why?
| | Young Adult | 21 | 2023 | 10795 | 0.510 |
Why?
| | Physical Endurance | 2 | 2013 | 231 | 0.500 |
Why?
| | Hyperemia | 5 | 2022 | 43 | 0.490 |
Why?
| | Humans | 57 | 2023 | 118983 | 0.490 |
Why?
| | Heart | 1 | 2018 | 631 | 0.480 |
Why?
| | Vasoconstriction | 6 | 2022 | 213 | 0.480 |
Why?
| | Thioctic Acid | 1 | 2013 | 8 | 0.470 |
Why?
| | Nitrates | 3 | 2022 | 78 | 0.450 |
Why?
| | Vitamin E | 1 | 2013 | 116 | 0.450 |
Why?
| | Male | 39 | 2023 | 57808 | 0.440 |
Why?
| | Arteries | 4 | 2023 | 250 | 0.440 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 5 | 0.440 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 6 | 0.440 |
Why?
| | Knee | 1 | 2012 | 52 | 0.430 |
Why?
| | Cross-Over Studies | 3 | 2023 | 456 | 0.400 |
Why?
| | Resistance Training | 2 | 2023 | 120 | 0.400 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 327 | 0.390 |
Why?
| | Diet, Western | 2 | 2021 | 69 | 0.390 |
Why?
| | Middle Aged | 17 | 2023 | 27623 | 0.380 |
Why?
| | Healthy Volunteers | 4 | 2021 | 201 | 0.370 |
Why?
| | Oxygen Consumption | 7 | 2018 | 586 | 0.370 |
Why?
| | Female | 26 | 2023 | 61574 | 0.370 |
Why?
| | Exercise Test | 3 | 2022 | 551 | 0.360 |
Why?
| | Blood Pressure | 7 | 2023 | 1664 | 0.340 |
Why?
| | Posture | 5 | 2016 | 158 | 0.340 |
Why?
| | Electromyography | 4 | 2014 | 326 | 0.340 |
Why?
| | Adult | 21 | 2023 | 31515 | 0.330 |
Why?
| | Caloric Restriction | 2 | 2020 | 91 | 0.320 |
Why?
| | Atherosclerosis | 3 | 2018 | 346 | 0.320 |
Why?
| | Hand Strength | 3 | 2023 | 99 | 0.300 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 204 | 0.290 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 526 | 0.280 |
Why?
| | Feedback, Physiological | 3 | 2014 | 75 | 0.260 |
Why?
| | Sympathetic Nervous System | 3 | 2023 | 171 | 0.260 |
Why?
| | Respiratory Muscles | 2 | 2023 | 36 | 0.260 |
Why?
| | Pulse Wave Analysis | 5 | 2023 | 216 | 0.250 |
Why?
| | Flavonols | 1 | 2023 | 10 | 0.240 |
Why?
| | Arterial Pressure | 5 | 2019 | 99 | 0.240 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 12 | 0.230 |
Why?
| | Adolescent | 7 | 2023 | 18479 | 0.220 |
Why?
| | Vaping | 1 | 2023 | 51 | 0.220 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 138 | 0.220 |
Why?
| | Endothelin-1 | 2 | 2016 | 168 | 0.220 |
Why?
| | Acetylcholine | 2 | 2023 | 208 | 0.220 |
Why?
| | Animals | 12 | 2023 | 33390 | 0.220 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 81 | 0.210 |
Why?
| | Treatment Outcome | 4 | 2022 | 9343 | 0.210 |
Why?
| | Age Factors | 4 | 2016 | 2995 | 0.210 |
Why?
| | Administration, Oral | 2 | 2015 | 756 | 0.210 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.200 |
Why?
| | Hypertension | 2 | 2021 | 1203 | 0.200 |
Why?
| | Breathing Exercises | 1 | 2021 | 22 | 0.200 |
Why?
| | Inhalation | 1 | 2021 | 27 | 0.200 |
Why?
| | Double-Blind Method | 3 | 2023 | 1687 | 0.200 |
Why?
| | Cardiovascular System | 3 | 2020 | 127 | 0.200 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 95 | 0.190 |
Why?
| | Inflammation | 5 | 2023 | 2566 | 0.190 |
Why?
| | Hypotension | 1 | 2022 | 120 | 0.190 |
Why?
| | Dementia | 1 | 2023 | 208 | 0.190 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 12 | 0.180 |
Why?
| | Pressoreceptors | 1 | 2019 | 18 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2021 | 187 | 0.180 |
Why?
| | Glucose Intolerance | 1 | 2021 | 139 | 0.180 |
Why?
| | Biomarkers | 3 | 2021 | 3588 | 0.170 |
Why?
| | Supine Position | 2 | 2016 | 39 | 0.170 |
Why?
| | Models, Animal | 1 | 2021 | 363 | 0.170 |
Why?
| | Mice | 8 | 2023 | 15520 | 0.170 |
Why?
| | Coronary Circulation | 1 | 2019 | 121 | 0.170 |
Why?
| | Athletes | 1 | 2022 | 353 | 0.170 |
Why?
| | Hemodynamics | 6 | 2023 | 1004 | 0.170 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 53 | 0.170 |
Why?
| | Electron Transport | 1 | 2018 | 101 | 0.170 |
Why?
| | Energy Metabolism | 2 | 2021 | 767 | 0.160 |
Why?
| | Fasting | 1 | 2020 | 264 | 0.160 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 260 | 0.160 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 25 | 0.160 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 59 | 0.160 |
Why?
| | Habits | 1 | 2017 | 38 | 0.150 |
Why?
| | Heart Rate | 6 | 2023 | 729 | 0.150 |
Why?
| | Bicycling | 2 | 2021 | 77 | 0.150 |
Why?
| | Coronary Vessels | 1 | 2019 | 233 | 0.150 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 192 | 0.150 |
Why?
| | Congresses as Topic | 1 | 2018 | 204 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 589 | 0.140 |
Why?
| | Metabolomics | 1 | 2021 | 550 | 0.140 |
Why?
| | Primary Prevention | 1 | 2018 | 185 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2874 | 0.130 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 468 | 0.130 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 41 | 0.130 |
Why?
| | Reflex | 1 | 2015 | 64 | 0.130 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 66 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 541 | 0.130 |
Why?
| | Life Style | 1 | 2017 | 430 | 0.130 |
Why?
| | Cell Respiration | 3 | 2021 | 76 | 0.130 |
Why?
| | Muscle Strength | 3 | 2023 | 283 | 0.130 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 4 | 0.130 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 20 | 0.130 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 36 | 0.120 |
Why?
| | Bronchoconstriction | 1 | 2014 | 26 | 0.120 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 104 | 0.120 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 27 | 0.120 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 52 | 0.120 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 32 | 0.120 |
Why?
| | Shear Strength | 1 | 2014 | 55 | 0.120 |
Why?
| | Cardiac Output | 4 | 2015 | 147 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 455 | 0.120 |
Why?
| | Extremities | 1 | 2014 | 113 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 374 | 0.120 |
Why?
| | Vital Capacity | 1 | 2014 | 260 | 0.120 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 83 | 0.110 |
Why?
| | Free Radicals | 1 | 2013 | 104 | 0.110 |
Why?
| | Recovery of Function | 1 | 2017 | 604 | 0.110 |
Why?
| | Fentanyl | 3 | 2021 | 70 | 0.110 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 457 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 647 | 0.110 |
Why?
| | Aorta | 3 | 2021 | 367 | 0.110 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 520 | 0.110 |
Why?
| | Single-Blind Method | 1 | 2013 | 269 | 0.110 |
Why?
| | Drug Combinations | 1 | 2013 | 291 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 253 | 0.110 |
Why?
| | Central Nervous System | 1 | 2014 | 245 | 0.100 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6561 | 0.100 |
Why?
| | Motor Activity | 3 | 2021 | 660 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 736 | 0.100 |
Why?
| | Motor Neurons | 1 | 2013 | 213 | 0.100 |
Why?
| | Knee Joint | 1 | 2014 | 353 | 0.100 |
Why?
| | Spinal Cord | 1 | 2013 | 367 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2019 | 3171 | 0.090 |
Why?
| | Sepsis | 1 | 2016 | 531 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4596 | 0.080 |
Why?
| | Biological Availability | 2 | 2021 | 126 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2023 | 4908 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 1968 | 0.070 |
Why?
| | Photoplethysmography | 2 | 2016 | 19 | 0.060 |
Why?
| | Fingers | 2 | 2016 | 83 | 0.060 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 46 | 0.060 |
Why?
| | Respiratory Therapy | 1 | 2023 | 19 | 0.060 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 225 | 0.060 |
Why?
| | Lower Extremity | 2 | 2019 | 335 | 0.060 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 198 | 0.060 |
Why?
| | Time Factors | 3 | 2021 | 6414 | 0.060 |
Why?
| | Forearm | 1 | 2023 | 117 | 0.060 |
Why?
| | Hypercapnia | 1 | 2023 | 50 | 0.060 |
Why?
| | Muscles | 1 | 2023 | 333 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 230 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2021 | 105 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 793 | 0.050 |
Why?
| | Nicotine | 1 | 2023 | 276 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2021 | 89 | 0.050 |
Why?
| | Blood Circulation | 1 | 2021 | 36 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 204 | 0.050 |
Why?
| | Mouth | 1 | 2021 | 74 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 344 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2021 | 184 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 829 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 12977 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 9 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 247 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3057 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 133 | 0.040 |
Why?
| | Oxygen | 1 | 2022 | 854 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 775 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 156 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 473 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 594 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 448 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2021 | 606 | 0.040 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 44 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 53 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 38 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 24 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 357 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 36 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1419 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1079 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 44 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 37 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1868 | 0.030 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 21 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 32 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 656 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 845 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4080 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 117 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2017 | 356 | 0.030 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 24 | 0.030 |
Why?
| | Femoral Vein | 1 | 2012 | 29 | 0.030 |
Why?
| | Physical Exertion | 1 | 2014 | 222 | 0.030 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 60 | 0.030 |
Why?
| | Tryptophan | 1 | 2013 | 139 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2014 | 443 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.030 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 107 | 0.030 |
Why?
| | Colorado | 1 | 2021 | 4196 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2012 | 356 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 536 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 282 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 716 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 608 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5115 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1570 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2750 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 6473 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 9001 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3004 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4552 | 0.020 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|